U.S., Dec. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07276373) titled 'Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies' on Dec. 01.
Brief Summary: This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Neoplasms
Intervention:
DRUG: Nenocorilant 200 mg
Nenocorilant 200 mg will be supplied as 50 and/or 100 mg tablets.
DRUG: Nenocorilant 300 mg
Nenocorilant 300 mg will be supplied ...